Viatris(VTRS) Prnewswire·2024-09-18 00:45Tender Offer Details - Viatris Inc announced the early tender results of its subsidiary Utah Acquisition Sub Inc's cash tender offer, increasing the maximum aggregate principal amount from $450,000,000 to $575,003,000 for its 3.950% Senior Notes due 2026 [1] - The aggregate principal amount of Maximum Tender Offer Notes validly tendered and not withdrawn by the Early Tender Date was $1,449,950,000, exceeding the Maximum Tender Cap of $575,003,000 [2][3] - UAS will accept tendered notes on a pro rata basis with a proration factor of 39.7% due to oversubscription [3][5] Tender Offer Terms and Timeline - The total consideration for accepted notes will be determined at 10:00 am on September 18, 2024, including an Early Tender Payment of $30 per $1,000 principal amount [4][6] - The Maximum Tender Early Settlement Date is anticipated to be September 20, 2024 [7] - The Maximum Tender Offer will expire at 5:00 pm on October 2, 2024, unless extended or terminated earlier [8] Company Financial Activities - Viatris satisfied and discharged the indenture for its 1.650% Senior Notes due 2025 on September 16, 2024 [11] - Mylan Inc issued a notice of redemption for all outstanding 2.125% Senior Notes due 2025, with redemption expected to be completed by October 16, 2024 [11] Company Overview - Viatris is a global healthcare company combining generics and brands to address healthcare needs worldwide, supplying medicines to approximately 1 billion patients annually [16] - The company has a diverse portfolio of medicines and a global supply chain, with headquarters in the US and global centers in Pittsburgh, Shanghai, and Hyderabad [16]